Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other brokerages have also weighed in on RGLS. Canaccord Genuity Group increased their target price on Regulus Therapeutics from $9.00 to $12.00 and gave […]

Leave a Reply

Your email address will not be published.

Previous post StockNews.com Begins Coverage on Eagle Bancorp Montana (NASDAQ:EBMT)
Next post Chicago White Sox acquire veteran Max Stassi to provide catching depth